Guangzhou Innocare Pharma Tech Co., Ltd.

X-rx, Inc.

Beijing Innocare Pharma Tech Co., Ltd.

Haihong Ni

Chong Liu

Xiangyang Chen

Yingxiang Gao

Mark J Mulvihill

Ce Wang

Matthew Clark

Anthony Dominic Keefe

Ying Victor Zhang

Mark Mulvihill

Lee Babiss

Louis Renzetti

Frank Ruebsam

Zhifeng Xie

Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).

Substituted nicotinimide inhibitors of BTK for treating cancer

Compounds of Formula I, as shown below and defined herein: 

Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease

The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancer, lymphocyte homing, chronic inflammation, neuropathic pain, fibrotic diseases, thrombosis, and cholestatic pruritus, mediated at least in part by ATX. 

Substituted spirocyclic inhibitors of autotaxin

The present invention relates to compounds according to Formula 1 and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancer, lymphocyte homing, chronic inflammation, neuropathic pain, fibrotic diseases, thrombosis, and cholestatic pruritus, mediated at least in part by ATX. 

Substituted nicotinamide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease

Growing community of inventors

Beijing, China

Haihong Ni